{"format":{"id":"tcr-t","name":"TCR-T cell therapies","blurb":"A T-cell receptor engineered to see a peptide from inside the cell presented on an HLA molecule: the antigen and the HLA restriction together decide who the medicine can treat.","route":"/modalities/tcr-t/","engine":"/pipeline/engine/tcr-t/"},"counts":{"drugs":5,"approved":1,"phase3":2,"trials":3,"companies":5,"papers":2,"ideas":8,"eras":3},"how":{"paragraphs":["T cells engineered with a receptor that sees fragments of proteins inside the cancer cell, reaching targets CAR-T cannot.","Transgenic αβ TCR recognises a peptide-HLA complex; restricted to patients with the matching HLA allele."],"from":[{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/"}],"technologies":[{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/","status":"approved","tldr":"T cells engineered with a receptor that sees fragments of proteins inside the cancer cell, reaching targets CAR-T cannot."}]},"terms":[],"engine":{"route":"/pipeline/engine/tcr-t/","axes":["Target","HLA restriction"],"rows":4,"cols":1,"counts":{"approved":1,"development":4,"stopped":0,"unclear":0,"untried":2},"placed":5,"total":5,"pct":100},"approved":[{"drug":{"id":"afamitresgene-autoleucel","kind":"drug","name":"Afamitresgene autoleucel","route":"/drugs/afamitresgene-autoleucel/"},"brand":"Tecelra","status":"approved","modality":"TCR-T (MAGE-A4)","cancers":[{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"},{"id":"synovial-sarcoma","kind":"cancer","name":"Synovial sarcoma","route":"/cancers/synovial-sarcoma/"}],"indications":["Advanced MAGE-A4+ synovial sarcoma, HLA-A*02+ (age ≥12 from 2026)"],"years":[2024],"firstYear":2024,"regions":["US"],"target":{"key":"target","id":"mage-a4","name":"MAGE-A4","href":"/targets/mage-a4/"},"companies":[{"id":"adaptimmune","kind":"company","name":"Adaptimmune","route":"/companies/adaptimmune/"},{"id":"us-worldmeds","kind":"company","name":"US WorldMeds","route":"/companies/us-worldmeds/"}]}],"phase3":[{"drug":{"id":"ima203","kind":"drug","name":"IMA203","route":"/drugs/ima203/"},"status":"phase-3","modality":"TCR-T cell therapy","cancers":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"target":{"key":"target","id":"prame","name":"PRAME","href":"/targets/prame/"},"trials":[{"id":"nct06743126","kind":"trial","name":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","route":"/trials/nct06743126/"}],"companies":[{"id":"immatics","kind":"company","name":"Immatics","route":"/companies/immatics/"}],"recruiting":2},{"drug":{"id":"tbi-1301","kind":"drug","name":"TBI-1301","route":"/drugs/tbi-1301/"},"status":"phase-3","modality":"TCR-T cell therapy (per the sponsor's pipeline page; form not stated in the registry record)","cancers":[{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"target":{"key":"target","id":"ctag1b","name":"CTAG1B","href":"/targets/ctag1b/"},"trials":[{"id":"nct07174427","kind":"trial","name":"Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma","route":"/trials/nct07174427/"}],"companies":[{"id":"takara-bio","kind":"company","name":"Takara Bio","route":"/companies/takara-bio/"}],"recruiting":1}],"components":[{"key":"target","label":"Target","values":[{"key":"target","id":"ctag1b","name":"CTAG1B","href":"/targets/ctag1b/","count":2,"drugIds":["letetresgene-autoleucel","tbi-1301"],"states":{"approved":0,"development":2,"stopped":0,"unclear":0}},{"key":"target","id":"cldn18-2","name":"Claudin 18.2","href":"/targets/cldn18-2/","count":1,"drugIds":["tac01-cldn18-2"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"mage-a4","name":"MAGE-A4","href":"/targets/mage-a4/","count":1,"drugIds":["afamitresgene-autoleucel"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"prame","name":"PRAME","href":"/targets/prame/","count":1,"drugIds":["ima203"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}}],"route":"/pipeline/engine/tcr-t/#table"},{"key":"hla","label":"HLA restriction","values":[{"key":"hla","id":"hla-a02","name":"HLA-A*02","href":"/targets/hla-a/","count":2,"drugIds":["afamitresgene-autoleucel","letetresgene-autoleucel"],"states":{"approved":1,"development":1,"stopped":0,"unclear":0}}],"route":"/pipeline/engine/tcr-t/#table"},{"key":"cellSource","label":"Cell source","values":[{"key":"cellSource","id":"autologous","name":"Autologous","count":3,"drugIds":["ima203","letetresgene-autoleucel","tac01-cldn18-2"],"states":{"approved":0,"development":3,"stopped":0,"unclear":0}}],"route":"/pipeline/engine/tcr-t/#table"},{"key":"format","label":"Format","values":[{"key":"format","id":"affinity-enhanced-tcr","name":"Affinity-enhanced TCR","href":"/technologies/tcr-t/","count":2,"drugIds":["afamitresgene-autoleucel","letetresgene-autoleucel"],"states":{"approved":1,"development":1,"stopped":0,"unclear":0}},{"key":"format","id":"tac","name":"T-cell antigen coupler","href":"/technologies/tcr-t/","count":1,"drugIds":["tac01-cldn18-2"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}}],"route":"/pipeline/engine/tcr-t/#table"}],"companies":[{"company":{"id":"us-worldmeds","kind":"company","name":"US WorldMeds","route":"/companies/us-worldmeds/"},"country":"US","companyType":"pharma","drugs":[{"id":"afamitresgene-autoleucel","kind":"drug","name":"Afamitresgene autoleucel","route":"/drugs/afamitresgene-autoleucel/"},{"id":"letetresgene-autoleucel","kind":"drug","name":"Letetresgene autoleucel","route":"/drugs/letetresgene-autoleucel/"}],"approved":1,"phase3":0},{"company":{"id":"adaptimmune","kind":"company","name":"Adaptimmune","route":"/companies/adaptimmune/"},"country":"GB","companyType":"cell-therapy","drugs":[{"id":"afamitresgene-autoleucel","kind":"drug","name":"Afamitresgene autoleucel","route":"/drugs/afamitresgene-autoleucel/"}],"approved":1,"phase3":0},{"company":{"id":"immatics","kind":"company","name":"Immatics","route":"/companies/immatics/"},"country":"DE","companyType":"cell-therapy","drugs":[{"id":"ima203","kind":"drug","name":"IMA203","route":"/drugs/ima203/"}],"approved":0,"phase3":1},{"company":{"id":"takara-bio","kind":"company","name":"Takara Bio","route":"/companies/takara-bio/"},"country":"JP","companyType":"cell-therapy","drugs":[{"id":"tbi-1301","kind":"drug","name":"TBI-1301","route":"/drugs/tbi-1301/"}],"approved":0,"phase3":1},{"company":{"id":"triumvira-immunologics","kind":"company","name":"Triumvira Immunologics","route":"/companies/triumvira-immunologics/"},"country":"US","companyType":"cell-therapy","drugs":[{"id":"tac01-cldn18-2","kind":"drug","name":"TAC01-CLDN18.2","route":"/drugs/tac01-cldn18-2/"}],"approved":0,"phase3":0}],"trials":[{"trial":{"id":"nct07174427","kind":"trial","name":"Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma","route":"/trials/nct07174427/"},"nct":"NCT07174427","phase":"3","status":"recruiting","setting":"Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma","sponsor":"Takara Bio","cancers":[{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"},{"id":"synovial-sarcoma","kind":"cancer","name":"Synovial sarcoma","route":"/cancers/synovial-sarcoma/"}],"drugs":[{"id":"tbi-1301","kind":"drug","name":"TBI-1301","route":"/drugs/tbi-1301/"}],"enrolled":5},{"trial":{"id":"nct06743126","kind":"trial","name":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","route":"/trials/nct06743126/"},"nct":"NCT06743126","phase":"3","status":"recruiting","setting":"A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus Investigator's Choice of Treatment in Patients With Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (ACTengine® IMA203-301)","sponsor":"Immatics US","cancers":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/"}],"drugs":[{"id":"ima203","kind":"drug","name":"IMA203","route":"/drugs/ima203/"}],"enrolled":360},{"trial":{"id":"nct05642455","kind":"trial","name":"SPEARHEAD-3 Pediatric Study","route":"/trials/nct05642455/"},"nct":"NCT05642455","phase":"1/2","status":"recruiting","setting":"A Phase 1/2 Open Label, Basket Study to Assess the Safety, Tolerability and Anti-Tumor Activity of Afamitresgene Autoleucel in Pediatric Subjects With MAGE-A4 Positive Tumors","sponsor":"USWM CT, LLC","cancers":[{"id":"osteosarcoma","kind":"cancer","name":"Osteosarcoma","route":"/cancers/osteosarcoma/"}],"drugs":[{"id":"afamitresgene-autoleucel","kind":"drug","name":"Afamitresgene autoleucel","route":"/drugs/afamitresgene-autoleucel/"}],"enrolled":20}],"registry":{"drugs":5,"recruiting":4,"fetched":"2026-09-21"},"sideEffects":{"terms":[{"id":"crs","kind":"term","name":"Cytokine release syndrome (CRS)","route":"/terms/crs/","tldr":"A flood of inflammatory signals when immune cells are activated en masse, causing fever, low blood pressure, and sometimes organ failure.","category":"Side effects","from":[{"id":"letetresgene-autoleucel","kind":"drug","name":"Letetresgene autoleucel","route":"/drugs/letetresgene-autoleucel/"}]}],"events":[{"group":"Cytokine release syndrome","drugs":1,"examples":[{"id":"afamitresgene-autoleucel","kind":"drug","name":"Afamitresgene autoleucel","route":"/drugs/afamitresgene-autoleucel/"}]},{"group":"Infections","drugs":1,"examples":[{"id":"afamitresgene-autoleucel","kind":"drug","name":"Afamitresgene autoleucel","route":"/drugs/afamitresgene-autoleucel/"}]},{"group":"Low blood counts (general)","drugs":1,"examples":[{"id":"afamitresgene-autoleucel","kind":"drug","name":"Afamitresgene autoleucel","route":"/drugs/afamitresgene-autoleucel/"}]},{"group":"Nausea or vomiting","drugs":1,"examples":[{"id":"afamitresgene-autoleucel","kind":"drug","name":"Afamitresgene autoleucel","route":"/drugs/afamitresgene-autoleucel/"}]},{"group":"Tiredness (fatigue)","drugs":1,"examples":[{"id":"afamitresgene-autoleucel","kind":"drug","name":"Afamitresgene autoleucel","route":"/drugs/afamitresgene-autoleucel/"}]}],"drugsWithToxicity":1},"resistance":[],"papers":[{"id":"paper-spearhead-1-afami-cel-sarcoma-lancet-2024","kind":"paper","name":"SPEARHEAD-1: afami-cel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma","route":"/key-papers/paper-spearhead-1-afami-cel-sarcoma-lancet-2024/","year":2024,"journal":"The Lancet","paperType":"translational","tldr":"T cells engineered with a receptor recognising the MAGE-A4 cancer antigen shrank tumours in 37% of patients with advanced synovial sarcoma or myxoid liposarcoma, leading to the first approval of a TCR-T therapy.","via":[{"id":"afamitresgene-autoleucel","kind":"drug","name":"Afamitresgene autoleucel","route":"/drugs/afamitresgene-autoleucel/"},{"id":"letetresgene-autoleucel","kind":"drug","name":"Letetresgene autoleucel","route":"/drugs/letetresgene-autoleucel/"},{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/"}]},{"id":"paper-spearhead-1-lancet-2024","kind":"paper","name":"SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma","route":"/key-papers/paper-spearhead-1-lancet-2024/","year":2024,"journal":"The Lancet","paperType":"rct","tldr":"T cells taken from patients and engineered to recognise the MAGE-A4 protein shrank tumours in about four in ten patients with advanced synovial sarcoma, leading to the first approval of a TCR T-cell therapy for any solid cancer.","via":[{"id":"afamitresgene-autoleucel","kind":"drug","name":"Afamitresgene autoleucel","route":"/drugs/afamitresgene-autoleucel/"},{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/"}]}],"eras":[{"roadmap":{"id":"cell-therapy-roadmap","kind":"roadmap","name":"Cell therapy roadmap: CD19 CAR-T → solid tumours → in vivo CAR","route":"/roadmaps/cell-therapy-roadmap/"},"era":"2024-2026","title":"Solid tumours: TIL, TCR-T, CAR-T","status":"current","step":3,"route":"/roadmaps/cell-therapy-roadmap/#story-step-2","refs":[{"id":"afamitresgene-autoleucel","kind":"drug","name":"Afamitresgene autoleucel","route":"/drugs/afamitresgene-autoleucel/"}]},{"roadmap":{"id":"cell-therapy-roadmap","kind":"roadmap","name":"Cell therapy roadmap: CD19 CAR-T → solid tumours → in vivo CAR","route":"/roadmaps/cell-therapy-roadmap/"},"era":"2028+","title":"Speculative","status":"speculative","step":5,"route":"/roadmaps/cell-therapy-roadmap/#story-step-4","refs":[{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/"}]},{"roadmap":{"id":"kras-roadmap","kind":"roadmap","name":"KRAS roadmap: undruggable → G12C → pan-RAS","route":"/roadmaps/kras-roadmap/"},"era":"2026-2029","title":"Approval and combinations","status":"emerging","step":4,"route":"/roadmaps/kras-roadmap/#story-step-3","refs":[{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/"}]}],"ideas":[{"id":"idea-fund-hospital-exemption-registry","kind":"idea","name":"Hospital-exemption cell therapies at scale, backed by a shared registry","route":"/ideas/idea-fund-hospital-exemption-registry/","maturity":"early-clinical","tldr":"European law already lets hospitals make advanced therapies for their own patients. Pair that with a shared outcomes registry so academic CAR-Ts and similar treatments can prove themselves without a commercial licence.","via":[{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/"}]},{"id":"idea-reg-public-cell-therapy-foundries","kind":"idea","name":"Public cell-therapy foundries at cancer centres for academics and start-ups","route":"/ideas/idea-reg-public-cell-therapy-foundries/","maturity":"early-clinical","tldr":"Building a cell-therapy factory costs tens of millions, so most good academic ideas never reach patients. Shared public facilities would give them a route to the clinic.","via":[{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/"}]},{"id":"idea-bio1-pmhc-bispecifics-public-drivers","kind":"idea","name":"Antibodies that see mutant KRAS and p53 fragments displayed on the cell surface","route":"/ideas/idea-bio1-pmhc-bispecifics-public-drivers/","maturity":"preclinical-evidence","tldr":"Cells chop up their internal proteins and display the pieces on their surface. That means even undruggable proteins inside the cell can be attacked from outside by the immune system.","via":[{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/"}]},{"id":"idea-tcr-t-beyond-hla-a2","kind":"idea","name":"Extending sarcoma TCR-T beyond HLA-A*02","route":"/ideas/idea-tcr-t-beyond-hla-a2/","maturity":"preclinical-evidence","tldr":"Today's engineered T-cell therapies for sarcoma only work in the ~40-50% of people with one particular HLA type; new receptors for other HLA types would open them to everyone.","via":[{"id":"afamitresgene-autoleucel","kind":"drug","name":"Afamitresgene autoleucel","route":"/drugs/afamitresgene-autoleucel/"},{"id":"letetresgene-autoleucel","kind":"drug","name":"Letetresgene autoleucel","route":"/drugs/letetresgene-autoleucel/"},{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/"}]},{"id":"idea-prame-tcr-beyond-a02","kind":"idea","name":"TCR therapeutics for non-HLA-A*02 patients","route":"/ideas/idea-prame-tcr-beyond-a02/","maturity":"preclinical-evidence","tldr":"Today's T-cell-receptor drugs only work for people with one tissue type. Building versions for the other common types would roughly double who can be treated.","via":[{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/"}]},{"id":"idea-neoantigen-immunogenicity-rules","kind":"idea","name":"What makes a neoantigen actually immunogenic?","route":"/ideas/idea-neoantigen-immunogenicity-rules/","maturity":"preclinical-evidence","tldr":"Vaccines can now encode dozens of a tumour's mutations, but only a minority provoke useful T cells. Learning the rules would make vaccines smaller, cheaper, and stronger.","via":[{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/"}]},{"id":"idea-moon-engineered-immune-surveillance","kind":"idea","name":"Engineered immune surveillance: long-lived programmed immune cells that patrol for early cancer","route":"/ideas/idea-moon-engineered-immune-surveillance/","maturity":"speculative","tldr":"For people at very high cancer risk, install a small population of engineered immune cells that live for years and destroy cells showing early cancer signals before a tumour forms.","via":[{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/"}]},{"id":"idea-splice-neoantigens","kind":"idea","name":"Shared splice-derived neoantigens as off-the-shelf vaccine targets","route":"/ideas/idea-splice-neoantigens/","maturity":"speculative","tldr":"Mutations in the RNA splicing genes SF3B1, SRSF2 and U2AF1 produce the same mis-spliced proteins in patient after patient with MDS, CLL or uveal melanoma. If fragments of those proteins are displayed on common HLA molecules and seen by T cells, one off-the-shelf vaccine or TCR-T therapy could serve every SF3B1-mutant patient instead of being built per person.","via":[{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/"}]}],"manufacturing":{"sites":[{"id":"bms-devens","name":"Bristol Myers Squibb Devens","operator":"Bristol Myers Squibb","operatorRoute":"/companies/bms/","ownership":"in-house","city":"Devens, Massachusetts","country":"US","capabilities":["cell-therapy","antibody-drug-substance"],"capabilityLabels":["Cell therapy","Antibody drug substance"],"drugs":[{"id":"idecabtagene-vicleucel","kind":"drug","name":"Idecabtagene vicleucel","route":"/drugs/idecabtagene-vicleucel/"},{"id":"lisocabtagene-maraleucel","kind":"drug","name":"Lisocabtagene maraleucel","route":"/drugs/lisocabtagene-maraleucel/"}],"source":{"label":"BMS manufacturing","url":"https://www.bms.com/"}},{"id":"cellares-south-sf","name":"Cellares Smart Factory","operator":"Cellares","operatorRoute":"/companies/cellares/","ownership":"cdmo","city":"South San Francisco, California","country":"US","capabilities":["cell-therapy"],"capabilityLabels":["Cell therapy"],"drugs":[],"source":{"label":"Cellares","url":"https://cellares.com/"}},{"id":"kite-el-segundo","name":"Kite El Segundo","operator":"Kite (Gilead)","operatorRoute":"/companies/gilead/","ownership":"in-house","city":"El Segundo, California","country":"US","capabilities":["cell-therapy"],"capabilityLabels":["Cell therapy"],"drugs":[{"id":"axicabtagene-ciloleucel","kind":"drug","name":"Axicabtagene ciloleucel","route":"/drugs/axicabtagene-ciloleucel/"}],"source":{"label":"Kite manufacturing","url":"https://www.kitepharma.com/"}},{"id":"kite-frederick","name":"Kite Frederick","operator":"Kite (Gilead)","operatorRoute":"/companies/gilead/","ownership":"in-house","city":"Frederick, Maryland","country":"US","capabilities":["cell-therapy","viral-vector"],"capabilityLabels":["Cell therapy","Viral vector"],"drugs":[{"id":"axicabtagene-ciloleucel","kind":"drug","name":"Axicabtagene ciloleucel","route":"/drugs/axicabtagene-ciloleucel/"}],"source":{"label":"Kite manufacturing","url":"https://www.kitepharma.com/"}},{"id":"kite-hoofddorp","name":"Kite Hoofddorp","operator":"Kite (Gilead)","operatorRoute":"/companies/gilead/","ownership":"in-house","city":"Hoofddorp","country":"NL","capabilities":["cell-therapy"],"capabilityLabels":["Cell therapy"],"drugs":[{"id":"axicabtagene-ciloleucel","kind":"drug","name":"Axicabtagene ciloleucel","route":"/drugs/axicabtagene-ciloleucel/"}],"source":{"label":"Kite manufacturing","url":"https://www.kitepharma.com/"}},{"id":"legend-raritan","name":"Legend Biotech and Janssen Raritan","operator":"Legend Biotech with Johnson & Johnson","operatorRoute":"/companies/legend-biotech/","ownership":"in-house","city":"Raritan, New Jersey","country":"US","capabilities":["cell-therapy"],"capabilityLabels":["Cell therapy"],"drugs":[{"id":"ciltacabtagene-autoleucel","kind":"drug","name":"Ciltacabtagene autoleucel","route":"/drugs/ciltacabtagene-autoleucel/"}],"source":{"label":"Legend Biotech","url":"https://www.legendbiotech.com/"}},{"id":"legend-ghent","name":"Legend Biotech Ghent (Tech Lane)","operator":"Legend Biotech with Johnson & Johnson","operatorRoute":"/companies/legend-biotech/","ownership":"in-house","city":"Ghent","country":"BE","capabilities":["cell-therapy"],"capabilityLabels":["Cell therapy"],"drugs":[{"id":"ciltacabtagene-autoleucel","kind":"drug","name":"Ciltacabtagene autoleucel","route":"/drugs/ciltacabtagene-autoleucel/"}],"source":{"label":"Legend Biotech","url":"https://www.legendbiotech.com/"}},{"id":"miltenyi-bergisch-gladbach","name":"Miltenyi Biotec","operator":"Miltenyi Biotec","operatorRoute":"/companies/miltenyi-biotec/","ownership":"cdmo","city":"Bergisch Gladbach","country":"DE","capabilities":["cell-therapy","viral-vector"],"capabilityLabels":["Cell therapy","Viral vector"],"drugs":[],"source":{"label":"Miltenyi Biotec","url":"https://www.miltenyibiotec.com/"}},{"id":"novartis-morris-plains","name":"Novartis Morris Plains","operator":"Novartis","operatorRoute":"/companies/novartis/","ownership":"in-house","city":"Morris Plains, New Jersey","country":"US","capabilities":["cell-therapy"],"capabilityLabels":["Cell therapy"],"drugs":[{"id":"tisagenlecleucel","kind":"drug","name":"Tisagenlecleucel","route":"/drugs/tisagenlecleucel/"}],"source":{"label":"Novartis cell therapy","url":"https://www.novartis.com/"}},{"id":"oxford-biomedica-oxford","name":"Oxford Biomedica Oxbox","operator":"Oxford Biomedica","operatorRoute":"/companies/oxford-biomedica/","ownership":"cdmo","city":"Oxford","country":"GB","capabilities":["viral-vector"],"capabilityLabels":["Viral vector"],"drugs":[],"source":{"label":"Oxford Biomedica","url":"https://www.oxb.com/"}}],"capabilities":["Cell therapy","Viral vector"],"chain":{"id":"cell-therapy","name":"Cell therapy","summary":"Apheresis, vector, closed manufacturing, cryopreservation and chain of identity, release testing, point of care and allogeneic banks.","route":"/manufacturing/#chain-cell-therapy","technologies":[{"id":"apheresis-starting-material","kind":"technology","name":"Apheresis and starting-material collection","route":"/technologies/apheresis-starting-material/"},{"id":"viral-vector-manufacturing","kind":"technology","name":"Viral vector manufacturing (lentiviral, retroviral, AAV)","route":"/technologies/viral-vector-manufacturing/"},{"id":"car-t-manufacturing-process","kind":"technology","name":"Autologous CAR-T manufacturing, batch by batch","route":"/technologies/car-t-manufacturing-process/"},{"id":"closed-automated-cell-manufacturing","kind":"technology","name":"Closed automated cell-therapy manufacturing","route":"/technologies/closed-automated-cell-manufacturing/"},{"id":"cell-therapy-cold-chain","kind":"technology","name":"Cryopreservation and cell-therapy cold chain","route":"/technologies/cell-therapy-cold-chain/"},{"id":"cell-therapy-orchestration-software","kind":"technology","name":"Cell-therapy orchestration and chain-of-identity software","route":"/technologies/cell-therapy-orchestration-software/"},{"id":"cell-therapy-release-testing","kind":"technology","name":"Cell-therapy release and potency testing","route":"/technologies/cell-therapy-release-testing/"},{"id":"point-of-care-cell-manufacturing","kind":"technology","name":"Point-of-care and decentralised cell manufacturing","route":"/technologies/point-of-care-cell-manufacturing/"},{"id":"allogeneic-cell-banks","kind":"technology","name":"Allogeneic cell banks: one donor, hundreds of doses","route":"/technologies/allogeneic-cell-banks/"}],"companies":[{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"},{"id":"gilead","kind":"company","name":"Gilead Sciences (incl. Kite)","route":"/companies/gilead/"},{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"},{"id":"legend-biotech","kind":"company","name":"Legend Biotech","route":"/companies/legend-biotech/"},{"id":"autolus","kind":"company","name":"Autolus Therapeutics","route":"/companies/autolus/"},{"id":"oxford-biomedica","kind":"company","name":"OXB (Oxford Biomedica)","route":"/companies/oxford-biomedica/"},{"id":"miltenyi-biotec","kind":"company","name":"Miltenyi Biotec","route":"/companies/miltenyi-biotec/"},{"id":"cytiva","kind":"company","name":"Cytiva (Danaher)","route":"/companies/cytiva/"},{"id":"lonza","kind":"company","name":"Lonza","route":"/companies/lonza/"},{"id":"cellares","kind":"company","name":"Cellares","route":"/companies/cellares/"},{"id":"cryoport","kind":"company","name":"Cryoport","route":"/companies/cryoport/"},{"id":"terumo-bct","kind":"company","name":"Terumo Blood and Cell Technologies","route":"/companies/terumo-bct/"},{"id":"cellectis","kind":"company","name":"Cellectis","route":"/companies/cellectis/"},{"id":"allogene","kind":"company","name":"Allogene Therapeutics","route":"/companies/allogene/"},{"id":"immunoact","kind":"company","name":"ImmunoACT","route":"/companies/immunoact/"}],"products":[{"id":"tisagenlecleucel","kind":"drug","name":"Tisagenlecleucel","route":"/drugs/tisagenlecleucel/"},{"id":"axicabtagene-ciloleucel","kind":"drug","name":"Axicabtagene ciloleucel","route":"/drugs/axicabtagene-ciloleucel/"},{"id":"lisocabtagene-maraleucel","kind":"drug","name":"Lisocabtagene maraleucel","route":"/drugs/lisocabtagene-maraleucel/"},{"id":"idecabtagene-vicleucel","kind":"drug","name":"Idecabtagene vicleucel","route":"/drugs/idecabtagene-vicleucel/"},{"id":"ciltacabtagene-autoleucel","kind":"drug","name":"Ciltacabtagene autoleucel","route":"/drugs/ciltacabtagene-autoleucel/"},{"id":"obecabtagene-autoleucel","kind":"drug","name":"Obecabtagene autoleucel","route":"/drugs/obecabtagene-autoleucel/"},{"id":"lifileucel","kind":"drug","name":"Lifileucel","route":"/drugs/lifileucel/"}]},"technologies":[]},"drugs":[{"id":"afamitresgene-autoleucel","kind":"drug","name":"Afamitresgene autoleucel","route":"/drugs/afamitresgene-autoleucel/"},{"id":"ima203","kind":"drug","name":"IMA203","route":"/drugs/ima203/"},{"id":"letetresgene-autoleucel","kind":"drug","name":"Letetresgene autoleucel","route":"/drugs/letetresgene-autoleucel/"},{"id":"tac01-cldn18-2","kind":"drug","name":"TAC01-CLDN18.2","route":"/drugs/tac01-cldn18-2/"},{"id":"tbi-1301","kind":"drug","name":"TBI-1301","route":"/drugs/tbi-1301/"}],"note":"Every section is read from existing corpus records and names them (from, via, exemplars, refs); a section with nothing behind it is empty. Medicines of a format are the open drug engine's (/pipeline/engine/); technologies are listed in src/lib/modular-formats.ts. CC BY-NC 4.0, attribute Data from OnCo (onco.cc). Not medical advice."}